MersV1, PascalFrancis, Corpus, bibRecord, 000067

Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination

Identifieur interne : 000067 ( PascalFrancis/Corpus ); précédent : 000066; suivant : 000068

Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination

Auteurs : Wing-Pui Kong ; LAN WU ; Timothy C. Wallstrom ; Will Fischer ; Zhi-Yong Yang ; Sung-Youl Ko ; Norman L. Letvin ; Barton F. Haynes ; Beatrice H. Hahn ; Bette Korber ; Gary J. Nabel

Source :

Journal of virology [ 0022-538X ] ; 2009.

RBID : Pascal:09-0131147

Descripteurs français

Pascal (Inist)
- Virus HIV1, Immunité cellulaire, Vaccin génétique, Virologie, SIDA.

English descriptors

KwdEn :
- AIDS, Cellular immunity, Genetic vaccine, HIV-1 virus, Virology.

Abstract

An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-538X`
A03		`1`		`@0 J. virol.`
A05				`@2 83`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination`
A11	`01`	`1`		`@1 KONG (Wing-Pui)`
A11	`02`	`1`		`@1 LAN WU`
A11	`03`	`1`		`@1 WALLSTROM (Timothy C.)`
A11	`04`	`1`		`@1 FISCHER (Will)`
A11	`05`	`1`		`@1 YANG (Zhi-Yong)`
A11	`06`	`1`		`@1 KO (Sung-Youl)`
A11	`07`	`1`		`@1 LETVIN (Norman L.)`
A11	`08`	`1`		`@1 HAYNES (Barton F.)`
A11	`09`	`1`		`@1 HAHN (Beatrice H.)`
A11	`10`	`1`		`@1 KORBER (Bette)`
A11	`11`	`1`		`@1 NABEL (Gary J.)`
A14	`01`			`@1 Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive @2 Bethesda, Maryland 20892-3005 @3 USA @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut. @Z 11 aut.`
A14	`02`			`@1 Los Alamos National Laboratory, MS K710, T-10 @2 Los Alamos, New Mexico 87545 @3 USA @Z 3 aut. @Z 4 aut. @Z 10 aut.`
A14	`03`			`@1 Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732 @2 Boston, Massachusetts 021153 @3 USA @Z 7 aut.`
A14	`04`			`@1 Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive @2 Durham, North Carolina 27710 @3 USA @Z 8 aut.`
A14	`05`			`@1 Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South @2 Birmingham, Alabama 35294 @3 USA @Z 9 aut.`
A14	`06`			`@1 Santa Fe Institute, 1399 Hyde Park Road @2 Santa Fe, New Mexico 87501 @3 USA @Z 10 aut.`
A20				`@1 2201-2215`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13592 @5 354000187296090140`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 58 ref.`
A47	`01`	`1`		`@0 09-0131147`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of virology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.
C02	`01`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Virus HIV1 @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 HIV-1 virus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 HIV-1 virus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Immunité cellulaire @5 05`
C03	`02`	`X`	`ENG`	`@0 Cellular immunity @5 05`
C03	`02`	`X`	`SPA`	`@0 Inmunidad celular @5 05`
C03	`03`	`X`	`FRE`	`@0 Vaccin génétique @5 06`
C03	`03`	`X`	`ENG`	`@0 Genetic vaccine @5 06`
C03	`03`	`X`	`SPA`	`@0 Vacuna genética @5 06`
C03	`04`	`X`	`FRE`	`@0 Virologie @5 07`
C03	`04`	`X`	`ENG`	`@0 Virology @5 07`
C03	`04`	`X`	`SPA`	`@0 Virología @5 07`
C03	`05`	`X`	`FRE`	`@0 SIDA @5 14`
C03	`05`	`X`	`ENG`	`@0 AIDS @5 14`
C03	`05`	`X`	`SPA`	`@0 SIDA @5 14`
C07	`01`	`X`	`FRE`	`@0 Virus immunodéficience humaine @2 NW`
C07	`01`	`X`	`ENG`	`@0 Human immunodeficiency virus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Human immunodeficiency virus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Lentivirus @2 NW`
C07	`02`	`X`	`ENG`	`@0 Lentivirus @2 NW`
C07	`02`	`X`	`SPA`	`@0 Lentivirus @2 NW`
C07	`03`	`X`	`FRE`	`@0 Retroviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Retroviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Retroviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Immunodéficit @5 13`
C07	`05`	`X`	`ENG`	`@0 Immune deficiency @5 13`
C07	`05`	`X`	`SPA`	`@0 Inmunodeficiencia @5 13`
C07	`06`	`X`	`FRE`	`@0 Virose`
C07	`06`	`X`	`ENG`	`@0 Viral disease`
C07	`06`	`X`	`SPA`	`@0 Virosis`
C07	`07`	`X`	`FRE`	`@0 Infection`
C07	`07`	`X`	`ENG`	`@0 Infection`
C07	`07`	`X`	`SPA`	`@0 Infección`
C07	`08`	`X`	`FRE`	`@0 Immunopathologie @5 17`
C07	`08`	`X`	`ENG`	`@0 Immunopathology @5 17`
C07	`08`	`X`	`SPA`	`@0 Inmunopatología @5 17`
N21				`@1 089`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0131147 INIST
ET :	Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination
AU :	KONG (Wing-Pui); LAN WU; WALLSTROM (Timothy C.); FISCHER (Will); YANG (Zhi-Yong); KO (Sung-Youl); LETVIN (Norman L.); HAYNES (Barton F.); HAHN (Beatrice H.); KORBER (Bette); NABEL (Gary J.)
AF :	Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive/Bethesda, Maryland 20892-3005/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 11 aut.); Los Alamos National Laboratory, MS K710, T-10/Los Alamos, New Mexico 87545/Etats-Unis (3 aut., 4 aut., 10 aut.); Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732/Boston, Massachusetts 021153/Etats-Unis (7 aut.); Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive/Durham, North Carolina 27710/Etats-Unis (8 aut.); Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South/Birmingham, Alabama 35294/Etats-Unis (9 aut.); Santa Fe Institute, 1399 Hyde Park Road/Santa Fe, New Mexico 87501/Etats-Unis (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2009; Vol. 83; No. 5; Pp. 2201-2215; Bibl. 58 ref.
LA :	Anglais
EA :	An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.
CC :	002A05C10
FD :	Virus HIV1; Immunité cellulaire; Vaccin génétique; Virologie; SIDA
FG :	Virus immunodéficience humaine; Lentivirus; Retroviridae; Virus; Immunodéficit; Virose; Infection; Immunopathologie
ED :	HIV-1 virus; Cellular immunity; Genetic vaccine; Virology; AIDS
EG :	Human immunodeficiency virus; Lentivirus; Retroviridae; Virus; Immune deficiency; Viral disease; Infection; Immunopathology
SD :	HIV-1 virus; Inmunidad celular; Vacuna genética; Virología; SIDA
LO :	INIST-13592.354000187296090140
ID :	09-0131147

Links to Exploration step

Pascal:09-0131147

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination</title>
<author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lan Wu" sort="Lan Wu" uniqKey="Lan Wu" last="Lan Wu">LAN WU</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wallstrom, Timothy C" sort="Wallstrom, Timothy C" uniqKey="Wallstrom T" first="Timothy C." last="Wallstrom">Timothy C. Wallstrom</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fischer, Will" sort="Fischer, Will" uniqKey="Fischer W" first="Will" last="Fischer">Will Fischer</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Zhi Yong" sort="Yang, Zhi Yong" uniqKey="Yang Z" first="Zhi-Yong" last="Yang">Zhi-Yong Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ko, Sung Youl" sort="Ko, Sung Youl" uniqKey="Ko S" first="Sung-Youl" last="Ko">Sung-Youl Ko</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Letvin, Norman L" sort="Letvin, Norman L" uniqKey="Letvin N" first="Norman L." last="Letvin">Norman L. Letvin</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732</s1>
<s2>Boston, Massachusetts 021153</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F." last="Haynes">Barton F. Haynes</name>
<affiliation><inist:fA14 i1="04"><s1>Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive</s1>
<s2>Durham, North Carolina 27710</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hahn, Beatrice H" sort="Hahn, Beatrice H" uniqKey="Hahn B" first="Beatrice H." last="Hahn">Beatrice H. Hahn</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South</s1>
<s2>Birmingham, Alabama 35294</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Korber, Bette" sort="Korber, Bette" uniqKey="Korber B" first="Bette" last="Korber">Bette Korber</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Santa Fe Institute, 1399 Hyde Park Road</s1>
<s2>Santa Fe, New Mexico 87501</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J." last="Nabel">Gary J. Nabel</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0131147</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0131147 INIST</idno>
<idno type="RBID">Pascal:09-0131147</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000067</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination</title>
<author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lan Wu" sort="Lan Wu" uniqKey="Lan Wu" last="Lan Wu">LAN WU</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wallstrom, Timothy C" sort="Wallstrom, Timothy C" uniqKey="Wallstrom T" first="Timothy C." last="Wallstrom">Timothy C. Wallstrom</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fischer, Will" sort="Fischer, Will" uniqKey="Fischer W" first="Will" last="Fischer">Will Fischer</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yang, Zhi Yong" sort="Yang, Zhi Yong" uniqKey="Yang Z" first="Zhi-Yong" last="Yang">Zhi-Yong Yang</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ko, Sung Youl" sort="Ko, Sung Youl" uniqKey="Ko S" first="Sung-Youl" last="Ko">Sung-Youl Ko</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Letvin, Norman L" sort="Letvin, Norman L" uniqKey="Letvin N" first="Norman L." last="Letvin">Norman L. Letvin</name>
<affiliation><inist:fA14 i1="03"><s1>Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732</s1>
<s2>Boston, Massachusetts 021153</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haynes, Barton F" sort="Haynes, Barton F" uniqKey="Haynes B" first="Barton F." last="Haynes">Barton F. Haynes</name>
<affiliation><inist:fA14 i1="04"><s1>Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive</s1>
<s2>Durham, North Carolina 27710</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hahn, Beatrice H" sort="Hahn, Beatrice H" uniqKey="Hahn B" first="Beatrice H." last="Hahn">Beatrice H. Hahn</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South</s1>
<s2>Birmingham, Alabama 35294</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Korber, Bette" sort="Korber, Bette" uniqKey="Korber B" first="Bette" last="Korber">Bette Korber</name>
<affiliation><inist:fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Santa Fe Institute, 1399 Hyde Park Road</s1>
<s2>Santa Fe, New Mexico 87501</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J." last="Nabel">Gary J. Nabel</name>
<affiliation><inist:fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Cellular immunity</term>
<term>Genetic vaccine</term>
<term>HIV-1 virus</term>
<term>Virology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus HIV1</term>
<term>Immunité cellulaire</term>
<term>Vaccin génétique</term>
<term>Virologie</term>
<term>SIDA</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>83</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KONG (Wing-Pui)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LAN WU</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WALLSTROM (Timothy C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FISCHER (Will)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>YANG (Zhi-Yong)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KO (Sung-Youl)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LETVIN (Norman L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HAYNES (Barton F.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HAHN (Beatrice H.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KORBER (Bette)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>NABEL (Gary J.)</s1>
</fA11>
<fA14 i1="01"><s1>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive</s1>
<s2>Bethesda, Maryland 20892-3005</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Los Alamos National Laboratory, MS K710, T-10</s1>
<s2>Los Alamos, New Mexico 87545</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732</s1>
<s2>Boston, Massachusetts 021153</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive</s1>
<s2>Durham, North Carolina 27710</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South</s1>
<s2>Birmingham, Alabama 35294</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Santa Fe Institute, 1399 Hyde Park Road</s1>
<s2>Santa Fe, New Mexico 87501</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>2201-2215</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000187296090140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>58 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0131147</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus HIV1</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>HIV-1 virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>HIV-1 virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Immunité cellulaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cellular immunity</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Inmunidad celular</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin génétique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Genetic vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna genética</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Virologie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Virology</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Virología</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>SIDA</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>AIDS</s0>
<s5>14</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>SIDA</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Immunodéficit</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Immune deficiency</s0>
<s5>13</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Inmunodeficiencia</s0>
<s5>13</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>17</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>17</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>17</s5>
</fC07>
<fN21><s1>089</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0131147 INIST</NO>
<ET>Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination</ET>
<AU>KONG (Wing-Pui); LAN WU; WALLSTROM (Timothy C.); FISCHER (Will); YANG (Zhi-Yong); KO (Sung-Youl); LETVIN (Norman L.); HAYNES (Barton F.); HAHN (Beatrice H.); KORBER (Bette); NABEL (Gary J.)</AU>
<AF>Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive/Bethesda, Maryland 20892-3005/Etats-Unis (1 aut., 2 aut., 5 aut., 6 aut., 11 aut.); Los Alamos National Laboratory, MS K710, T-10/Los Alamos, New Mexico 87545/Etats-Unis (3 aut., 4 aut., 10 aut.); Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P.O. Box 15732/Boston, Massachusetts 021153/Etats-Unis (7 aut.); Duke Human Vaccine Institute, Duke University Medical Center, MSRBII Building Room 4085, P.O. Box 103020, Research Drive/Durham, North Carolina 27710/Etats-Unis (8 aut.); Department of Medicine, University of Alabama at Birmingham, Kaul 816, 720 20th Street South/Birmingham, Alabama 35294/Etats-Unis (9 aut.); Santa Fe Institute, 1399 Hyde Park Road/Santa Fe, New Mexico 87501/Etats-Unis (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of virology; ISSN 0022-538X; Etats-Unis; Da. 2009; Vol. 83; No. 5; Pp. 2201-2215; Bibl. 58 ref.</SO>
<LA>Anglais</LA>
<EA>An effective AIDS vaccine must control highly diverse circulating strains of human immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) protein contains variable as well as conserved regions. In this report, an informatic approach to the design of T-cell vaccines directed to HIV-1 Env M group global sequences was tested. Synthetic Env antigens were designed to express mosaics that maximize the inclusion of common potential T-cell epitope (PTE) 9-mers and minimize the inclusion of rare epitopes likely to elicit strain-specific responses. DNA vaccines were evaluated using intracellular cytokine staining in inbred mice with a standardized panel of highly conserved 15-mer PTE peptides. One-, two-, and three-mosaic sets that increased theoretical epitope coverage were developed. The breadth and magnitude of T-cell immunity stimulated by these vaccines were compared to those for natural strain Envs; additional comparisons were performed on mutant Envs, including gp160 or gp145 with or without V regions and gp41 deletions. Among them, the two- or three-mosaic Env sets elicited the optimal CD4 and CD8 responses. These responses were most evident in CD8 T cells; the three-mosaic set elicited responses to an average of eight peptide pools, compared to two pools for a set of three natural Envs. Synthetic mosaic HIV-1 antigens can therefore induce T-cell responses with expanded breadth and may facilitate the development of effective T-cell-based HIV-1 vaccines.</EA>
<CC>002A05C10</CC>
<FD>Virus HIV1; Immunité cellulaire; Vaccin génétique; Virologie; SIDA</FD>
<FG>Virus immunodéficience humaine; Lentivirus; Retroviridae; Virus; Immunodéficit; Virose; Infection; Immunopathologie</FG>
<ED>HIV-1 virus; Cellular immunity; Genetic vaccine; Virology; AIDS</ED>
<EG>Human immunodeficiency virus; Lentivirus; Retroviridae; Virus; Immune deficiency; Viral disease; Infection; Immunopathology</EG>
<SD>HIV-1 virus; Inmunidad celular; Vacuna genética; Virología; SIDA</SD>
<LO>INIST-13592.354000187296090140</LO>
<ID>09-0131147</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000067 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0131147
   |texte=   Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination

Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri